Relief Therapeutics Holding AG (RLFTF)

[mc67]

translated
https://de.marketscreener.com/RELIEF-THERAPEUTICS-HOLDI-5527488/news/Relief-Therapeutics-VRP-sieht-bei-Corona-Mittel-Millionen-Potenzial-31089047/


MarketScreener Homepage > Equities > Swiss Exchange > Relief Therapeutics Holding AG RLF CH0100191136
Schweiz RELIEF THERAPEUTICS HOLDING AG (RLF) Add to watchlist
Report
verzögerte Kurse. Delayed Swiss Exchange - 08/10 17:31:08
0.7 Chf +20.69%

08:56 Relief Therapeutics-VRP sees millions of potential in Corona funds
Aw
08:46 Equities Switzerland Pre-Exchange:SMI slightly higher expected
Aw
07.08. Equities Switzerland Close:SMI little changed - US data only temporarily support
Aw
Overview Courses Charts News Company Finance Derivatives
News overview News Press releases Official publications Industry news

Relief Therapeutics-VRP sees millions of potential in Corona funds
share with twitter share with LinkedIn share with facebook
0
08/10/2020 | 08:56
Geneva (awp) - Relief Therapeutics, until recently the least known, could soon become an established pharmaceutical company. The active substance Aviptadil, which is intended to treat Covid-19, could inject more than 100 million Swiss francs into the coffers of the Geneva-based company, according to Chairman raghuram Selvaraju. An application for authorisation could be submitted in the USA in just a few months.

Relief was able to advance the clinical program for the active substance very quickly. "We are now seeing the first signs that our drug Aviptadil is working," Selvaraju said in an interview with the online portal "The Market" over the weekend.

The Chairman of the Board of Directors estimates the sales potential for Aviptadil to be "much more than 100 million Swiss francs" per year. The disease is likely to last a few more years, but eventually disappear. In this environment, it is very likely that Aviptadil's peak annual turnover would be much higher than the 100 million Swiss francs mentioned above.

Pricing, of course, depends on the competitive landscape and whether an effective vaccine will be available. Even with effective vaccination, however, it would take several years for such a widely used vaccine to be used.

"Our drug would therefore have a potential four to six years for patients who are seriously ill, and it could bring in hundreds of millions a year during this period," said Selvaraju, who is also a full-time healthcare analyst at U.S. investment firm H.C. Wainwright & Co.

Phase IIb/III study underway in the US

Relief Therapeutics holds the patents valid in the USA and Europe for Aviptadil. "In both markets, we also have orphan drug status," Selvaraju said.

In the US, Aviptadil is in a Phase IIb/III study aimed at patients who are severely ill with the consequences of Covid-19. Relief had received permission from the U.S. Food and Drug Administration (FDA) for a "Compassionate Access Program."

"The study we are working on has registration quality. If successful, it could be the basis for FDA approval," Selvaraju said. Relief is expected to take only a few months to get to a point where initial results from this study could be presented.

Optimistic about approval

In the case of meaningful data, the FDA should act pragmatically and cooperatively. 'I don't think we'll have to wait 10 to 12 months for an approval notice.'

He assesses the probability of admission at the moment to 60 to 70 percent. Since the active ingredient has been used for various indications for many years, the company is quite optimistic about its safety, says the Chairman of the Board of Directors.

The clinical development program for Aviptadil is conducted by the US development company NeuroRx. Relief assumes all costs for the studies. The Swiss company has sufficient access to funds in cash and, thanks to the high liquidity of the shares, in order to be able to pay for the studies on its own. Relief could also place approved share capital on the market.

The current stock market valuation of more than one billion Swiss francs is justified, Selvaraju continues. Until a few months ago, the market capitalization amounted to only about two million Swiss francs.

Thanks to Aviptadil, it has now exploded. On Friday, the stock closed at 0.58 Swiss francs on the Swiss stock exchange, having only been quoted at 0.001 Swiss francs at the end of 2019.

pre/kw


share with twitter share with LinkedIn share with facebook
0
Latest news about RELIEF THERAPEUTICS HOLDIN
08:56 Relief Therapeutics-VRP sees millions of potential in Corona funds
Aw
08:46 Equities Switzerland Pre-Exchange:SMI slightly higher expected
Aw
07.08. Equities Switzerland Close:SMI little changed - US data only temporarily support
Aw
07.08. Korr Equities Switzerland:Investors take courage ahead of US labour market data
Aw
06.08. Equities Switzerland Close:Third consecutive day of losses - Beirut weighs on Swiss R.
Aw
06.08. RELIEF THERAPEUTICS : FDA grants IND approval for treatment moderately difficult to ..
Bu
06.08. Equities Switzerland: Slightly weaker - Investors on hold
Aw
06.08. RELIEF: FDA approves RLF-100 to inhale corona disease
Aw
04.08. RELIEF THERAPEUTICS : Clinical study with RLF-100 (Aviptadil) showed rapid growth.
Bu
04.08. Equities Switzerland:Investors silver-plate in calm market previous day's profits
Aw
More news
News in English about RELIEF THERAPEUTICS HOLDIN
08.08. RELIEF THERAPEUTICS : sees 60-70% chance of COVID-19 drug approval
Re
06.08. RELIEF THERAPEUTICS : FDA grants inhaled use IND for RLF-100 (aviptadil) to trea..
Pr
04.08. GLOBAL MARKETS LIVE: Walt Disney, Bayer and BP's results

03.08. RELIEF THERAPEUTICS : RLF-100 (aviptadil) clinical trial showed rapid recovery f..
Bu
03.08. Relief, NeuroRx say emergency treatment with RLF-100 helps critically ill Cov..
Re
02.08. RELIEF THERAPEUTICS : RLF-100 (aviptadil) clinical trial showed rapid recovery f..
Pr
29.07. RELIEF THERAPEUTICS : FDA grants Expanded Access Protocol to RLF-100 (Aviptadil)..
Bu
29.07. FDA GRANTS EXPANDED ACCESS PROTOCOL : Currently in development by NeuroRx and R..
Pr
16.07. RELIEF THERAPEUTICS : NeuroRx and Relief Therapeutics Announce Data Monitoring ..
Bu
02.06. GLOBAL MARKETS LIVE: Did insiders sell Gilead Sciences?

More news in English
Financial indicators
CHF
Sales 2019 -
Net income 2019 -7.46 million
Net debt 2019 1.61 million
P/E 2019 -0.28x
Dividend yield 2019 -
Market capitalization 1 335 million
Market cape. / Sales 2018 20.5x
Market cape. / Sales 2019 -
Employees 10
Free float 58,9%
More financial indicators
Chart RELIEF THERAPEUTICS HOLDING AG
Duration:
Car.
Period:
Day

Relief Therapeutics Holding AG : Chartanalyse Relief Therapeutics Holding AG | MarketScreener
Full screen chart
Trends from chart analysis RELIEF THERAPEUTICS HOLDIN
Short term Medium term Long term
Trends Upgrade Upgrade Upgrade
Chart analysis
Earnings
Millions of CHF
Sales
Net income
Rate of net profitability
2015
2016
2017
2018
2019
-20
-18
-15
-13
-10
-8
-5
-3
0
3
-150000%
-100000%
-50000%
0%
©marketscreener.com - S&P Global Market Intelligence
More financial indicators
Management
Name Title
Raghuram Selvaraju Chairman
Yves Sagot Chief Scientific Officer
Peter Egon de Svastich Director
Jonathan C. Javitt Vice Chairman
More information about the company
Industry and competitors
01.01. Market Capitalization (M)

Schweiz RELIEF THERAPEUTICS HOLDING AG 57,900.00% 1 463

Schweiz LONZA GROUP 61.66% 46 473
Korea, Republik CELLTRION, INC. 73.76% 35 375
Vereinigte Staaten IQVIA HOLDINGS INC. 3.90% 30 707
Vereinigte Staaten MODERNA, INC. 278.83% 29 239
Vereinigte Staaten SEATTLE GENETICS, INC. 40.43% 27 918
More results
World Europe America Asia

Dax 12687.53 0.10% verzögerte Kurse.
Mdax 27175 0.12% verzögerte Kurse.
Tecdax 3028 -0.95% verzögerte Kurse.
Sdax 12203 0.05% verzögerte Kurse.
EURO STOXX 50 3260 0.22% verzögerte Kurse.
S&P 500 3360 0.27% verzögerte Kurse.
DOW JONES 27791 1.30% verzögerte Kurse.
NASDAQ 100 11085 -0.49% verzögerte Kurse.
CAC 40 4910 0.41% Realtime Kurse.
More indices
Watchlist
Popular Stocks
VARTA AG 6.18% verzögerte Kurse.
ROYAL DUTCH SHE.. 2.22% verzögerte Kurse.
BASF SE 1.65% verzögerte Kurse.
APPLE INC. 1.45% verzögerte Kurse.
BAYER AG 1.09% verzögerte Kurse.
Facebook -2.03% verzögerte Kurse.
TESLA, INC. -2.35% verzögerte Kurse.
NEL ASA -3.26% verzögerte Kurse.
WIRECARD AG -4.51% verzögerte Kurse.
TENCENT HOLDING.. -4.83% Schlusskurs.
Create your own watchlist
Top / Flop
DAX
de MTU AERO ENGINES AG 4.46% verzögerte Kurse.
de DEUTSCHE BANK AG 3.61% verzögerte Kurse.
de CONTINENTAL AG 2.46% verzögerte Kurse.
de HEIDELBERGCEMENT AG 2.29% verzögerte Kurse.
de ADIDAS AG 1.76% verzögerte Kurse.
MERCK KGAA -0.97% verzögerte Kurse.
SAP SE -1.66% verzögerte Kurse.
DEUTSCHE BÖRSE AG -2.11% verzögerte Kurse.
INFINEON TECHNOLOGIES AG -2.40% verzögerte Kurse.
WIRECARD AG -4.51% verzögerte Kurse.
IndustryIndustry
Health CareHealth Care
CommoditiesRaw materials
TechnologyTechnology
Collective servicesCollective services
CyclicalConsumer GoodsCyclicalConsumerGoods
FinanceFinance
Continuation Top / Flop
Top / Flop
Stoxx Europe 600
es BANCO DE SABADELL, S.A. 9.41% Schlusskurs.
de TUI AG 8.47% verzögerte Kurse.
gb INTERNATIONAL CONSOLIDATED AIRLINES GROUP, SA 8.38% verzögerte Kurse.
fr CNP ASSURANCES 7.42% Realtime Kurse.
gb MARKS & SPENCER GROUP PLC 6.47% verzögerte Kurse.
GALAPAGOS NV -4.06% verzögerte Kurse.
ADYEN N.V. -4.07% verzögerte Kurse.
HARGREAVES LANSDOWN PLC -4.24% verzögerte Kurse.
EVOLUTION GAMING GROUP AB -4.37% verzögerte Kurse.
HELLOFRESH SE -5.32% verzögerte Kurse.
CyclicalConsumer GoodsCyclicalConsumerGoods
CommoditiesRaw materials
IndustryIndustry
TechnologyTechnology
FinanceFinance
Non-cyclicalconsumer goodsand DLnon-cyclicalconsumer goodsand DL
Telecommunications servicesTelecommunications services
Health CareHealth Care
Continuation Top / Flop
Foreign Exchange / Forex

EUR / USD 1.17398 -0.35% verzögerte Kurse.
EUR / CHF 1.07463 -0.06% verzögerte Kurse.
USD / JPY 105.96 +0.10% verzögerte Kurse.
GBP / USD 1.30722 +0.17% verzögerte Kurse.
EUR / GBP 0.89796 -0.53% verzögerte Kurse.
EUR / JPY 124.391 -0.25% verzögerte Kurse.
AUD / USD 0.7149 -0.08% verzögerte Kurse.
Currencies
Raw Materials

Gold 2028.33 +0.07% verzögerte Kurse.
Wti 41.975 +0.89% verzögerte Kurse.
Brent 44.9500 0.56% verzögerte Kurse.
Silver 29.057 +3.34% verzögerte Kurse.
Platinum 982.302 +1.76% verzögerte Kurse.
Nickel 12685.0000 -0.12% Schlusskurs.
Corn 310.5000 0.89% Schlusskurs.
Raw materials
Cryptocurrencies

Bitcoin 11828.8800 2.12% Realtime Kurse.
ETHEREUM 394.9950 4.12% Realtime Kurse.
Ripple 0.2945 0.11% Realtime Kurse.
Cryptocurrencies